Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-Ascending Dose Study of LY3437943 in Japanese Participants with Type 2 Diabetes Mellitus
jRCT2051210029Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing LY3437943 with Placebo (2 arms). Primary endpoint: Serious adverse events related to study drug. Started Jun 2021; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2051210029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210029.